Stocks & ETFs

Latest News

Blogs & Articles

Stratagy Backtesting

Portfolio Analyser

Price Analyser

Compare Stocks

Stock & ETF Screener

Pricing

About The Company

Market Cap

23.94 Billion EUR

Sector

Healthcare

Website

https://www.coloplast.dk/

Description

Coloplast A/S develops, manufactures, and markets medical products.

Read More

Overview

Value

10

Growth

38

Health

50

Management

69

Analyst Opinion

89

Total

51

All Scores Out Of 100

Best Features

  • Liked by analysts
  • Has strong dividend growth

Risk Factors

  • Overvalued on cashflow basis
  • Earnings have declined recently
  • There is a history of diluting shareholders
  • Has a high level of debt
  • No margin of safety at their current market price
  • Poor earnings and cashflow growth
  • Price-to-earnings ratio of 38.2 is higher than the market average (19.6x)
  • High preportion of income is paid as dividend

Market Peers

CBHD.DE

Key Figures

PE Ratio (TTM)

38.21

Margin Of Safety (DCF)

-51.82%

Revenue Growth (5 Year Average)

9.06%

Ratings Consensus

Strong Buy

Share Buybacks

-0.05%

Dividend Yeild (TTM)

2.25%

Valuation

Value Score

10

  • Estimated intrinsic-value of 54.76 EUR is lower than current price ( 113.00 EUR)
  • Price-to-earnings ratio of 38.2 is higher than the market average (19.6x)
  • Free-cashflow-yeild of 2.21% is worse than the market average (4.7%)
  • Margin-of-safety of -51.82% is worse than the market average (17.95%)

Desired Margin Of Safety

0%

Tip: Set your desired Margin Of Safety

Free Cash Flow Type

Annual Cashflow Growth

0%

Discount Rate

0%

Buy Target: < 479.3 EUR

Current Price: 113.7 EUR

How Does This Work?

Show Advanced Options

This calculator helps investors estimate the Intrinsic Value of a company based on the current value of future cash flows. To use the tool, simply input a desired Margin Of Safety, which is an additional discount applied to the present value of the expected future cash flows. The tool calculates the present value using a discount rate that reflects the risk and time value of money, and provides an estimated target price for the company based on the selected margin of safety. The calculator defaults to using 5 Year Free Cash Flow Growth % and a discount rate based on the US 10-year treasury bond coupon rate. Use our performance analyser to get a feel the impact this has on longterm investment returns and discover a margin of safety you are comfortable with. This can be a useful tool for investors looking to make informed decisions about whether to buy or sell shares of a particular company.

Price/Earnings

38.21x

Free Cashflow Yeild

2.21%

PE/Earnings Growth

N/A

Price/Book

2.90x

Growth

Growth Score

38

  • Revenue growth has improved this yeara
  • Free Cashflow growth has improved this year
  • 5 Year Average Revenue growth of 9.06% is lower than the market average (10.97%)
  • 5 Year Average Earnings growth of 8.16% is lower than the market average (14.48%)
  • Earnings growth has slowed this year
  • 5 Year Average Free Cashflow growth of 2.88% is lower than the market average (12.35%)

Revenue Growth

9.06%

Earnings Growth

8.16%

Cashflow Growth

2.88%

Health

Health Score

50

  • Assets cover liabilities
  • Debt repayments do not significantly impact cashflow
  • Has a high level of debt
  • High financial leverage and base interest rate exposure
  • Requires debt for normal operation to be sustainable

Altman Z Score

2.05

Piostroski Score

6.00

Debt/Equity

2.26x

Current Assets/Liabilities

1.20x

Free Cashflow/Total Debt

0.21x

Debt/Capital

2.13x

Dividend

Secure Dividend Score

50

  • Dividend yeild of 2.25% is more than the market average (1.85%)
  • At risk of being unsafe
  • Dividends have shown growth over the last 5 years
  • Long term dividend payout ratio of 84.91% is high and may limit growth
  • Payout ratio (TTM) of 85.87% is higher than the average (40%)
  • Dividend growth has been slowing recently
  • Spending a higher percentage of their income on dividends than last 5 years

Dividend Yeild

2.25%

Dividend Growth

5.51%

Payout Ratio (Earnings)

85.87%

Payout Ratio (Cashflow)

101.94%

Management

Management Score

69

  • Has issued new shares to finance growth when share price is high
  • Has returned higher dividends when earnings have risen
  • Return-on-equity of 56.57% is higher than the market average (15%)
  • Return-on-capital-employed of 19.29% is higher than the market average (10%)
  • Has a history of diluting shareholders to finance activity

Average Buybacks/Dilution

-0.05%

Recent Buybacks/Dilution

-0.33%

5 Year Price Volitility

20.73%

Return On Assets

13.42%

Return On Capital Employed

19.29%

Return On Equity

56.57%

Return On Free Cashflow

141.11%

Return On Investments

9197.07%

Analysts

Analyst Opinion

89

  • Ratings consensus is Strong Buy

SEC Filings

Find yearly (10-K), quaterly (10-Q) and disclosure (8-K) report here, on the Securities and Exchange Commission's EDGAR database. If reading through reports isn't your cup of tea, don't worry. We've made it easy for you by summarizing all the important bits.

Other Information

Company Name

Coloplast A/S

Currency

EUR

Beta

0.80238

Vol Avg

157

Ceo

Cik

Cusip

K16018192

Exchange

XETRA

Full Time Employees

12000

Industry

Health Care Equipment & Services

Sector

Healthcare

Ipo Date

1983-01-01

Address

Holtedam 1-3

City

Humlebaek

State

Country

DK

Zip

Phone

4549111111

All financial data provided by FMP

Noticed an error with something on our site?

We Use Cookies